Objective: The aim of this study was to evaluate whether intratumoral human equilibrative nucleoside transporter 1 (hENT1) expression can predict the survival of advanced cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy (AGC) after surgical resection. Background: There have been no reports concerning a useful predictive biomarker in patients with cholangiocarcinoma treated with adjuvant gemcitabine chemotherapy. Methods: Intratumoral hENT1 expression was investigated immunohistochemically in 105 patients with resected advanced cholangiocarcinoma. Relationships between intratumoral hENT1 expression and clinicopathological factors were evaluated by univariate and multivariate analyses. This study was a retrospective analysis on retrospectively collected tissue and data. Results: Fifty-one patients received AGC, and 54 did not. High and low intratumoral hENT1 expression was found in 74 (70%) and 31 patients (30%), respectively. There were no significant differences in clinicopathological factors between patients with high hENT1 expression and those with low hENT1 expression. Survival patients with high hENT1 expression were significantly better than those with low hENT1 expression among patients who received AGC (P = 0.008), but not among patients who did not (P = 0.894). Moreover, a significant difference in survival between patients who received AGC and those who did not was observed among patients with high hENT1 expression (P = 0.002), but not among patients with low hENT1 expression (P = 0.525). Intratumoral hENT1 expression was only an independent predictive factor for patients treated with AGC by multivariate analysis (P = 0.027). Conclusions: Intratumoral hENT1 expression may be a potent predictive marker for advanced cholangiocarcinoma patients treated with AGC.
section. Moreover, the outcomes after surgical resection are not always satisfactory. Recent reports from high volume centers indicated that 5-year survival rates after surgical resection ranged from 21% to 48% for intrahepatic cholangiocarcinoma, [4] [5] [6] 30% to 42% for perihilar cholangiocarcinoma, [7] [8] [9] and 26% to 44% for distal cholangiocarcinoma, [10] [11] [12] even when extensive surgical procedures such as major hepatectomy, vascular resection, and extended lymphadenectomy were performed. Adjuvant therapeutic strategies are mandatory to improve survival after resection of cholangiocarcinoma.
Gemcitabine is the most commonly used chemotherapeutic agent in patients with unresectable 13 or resected 14, 15 pancreatic carcinoma, and it is considered a reasonable agent for the treatment of biliary carcinoma because the exocrine pancreas and biliary duct/gallbladder share a common embryological origin. Recently, results of several randomized controlled studies have demonstrated that gemcitabine, or gemcitabine-based chemotherapy, has an excellent survival benefit for patients with unresectable biliary carcinoma. 16, 17 However, no prospective studies have demonstrated the efficacy of gemcitabine for patients with cholangiocarcinoma in an adjuvant setting, and no standard adjuvant therapy after resection of cholangiocarcinoma has been established. In our institution, postoperative adjuvant chemotherapy with gemcitabine has been administered to patients with advanced biliary carcinoma since 2002, 18 and significant survival benefits of this adjuvant chemotherapy have been reported. 4, 7, 19 However, the efficacy of adjuvant gemcitabine varies among individuals. Therefore, identification of a useful predictive biomarker is needed to select an optimal adjuvant chemotherapy regimen for these patients. Recently, several investigators have reported the impact of intratumoral human equilibrative nucleoside transporter 1 (hENT1), which is the major transporter responsible for gemcitabine uptake into cells, 20, 21 on the gemcitabine treatment response of various malignant tumors. [22] [23] [24] [25] [26] [27] In addition, immunohistochemical analysis of hENT1 has been shown to be predictive of benefit from gemcitabine chemotherapy in biliary carcinoma. 28, 29 However, these were small-scale studies, and no reports have demonstrated a relationship between intratumoral hENT1 expression and outcomes in cholangiocarcinoma patients who received adjuvant gemcitabine chemotherapy after surgical resection. The aim of this study was to investigate whether intratumoral hENT1 expression could predict the survival of advanced cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy (AGC) after surgical resection. a confirmed pathological diagnosis. Of the 131  patients, 23, 62, 23, and 23 patients had International Union Against  Cancer (UICC) stage 30 I, II, III, and IV disease, respectively. In the  current study, advanced cholangiocarcinoma is defined as resectable  cholangiocarcinoma with UICC stage II, III, or IV disease, and patients with UICC stage II, III, or IV disease were analyzed. Three patients with perihilar cholangiocarcinoma were excluded because of operative deaths. Distant metastases or peritoneal dissemination were also criteria for exclusion from the study, even if they were resected. However, patients with para-aortic lymph node metastasis alone, which was diagnosed only by postoperative pathological examination and not by preoperative imaging examinations, were included. As a result, 105 patients were enrolled. The immunohistochemical staining of intratumoral hENT1 was performed on the resected specimens of all 105 patients. Relationships between intratumoral hENT1 expression and clinicopathological factors, including use of AGC or patient survival, were evaluated by univariate and multivariate analysis. Written informed consent was obtained from all patients for surgical treatment and pathological examinations according to the institutional guidelines.
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Surgical Procedures
Most patients with distal cholangiocarcinoma underwent pancreatoduodenectomy with or without pylorus preservation, whereas patients with intrahepatic or perihilar cholangiocarcinoma almost always underwent major hepatectomy, including hemihepatectomy and trisectionectomy. All surgical procedures for perihilar cholangiocarcinoma included caudate lobectomy. Dissection of the regional lymph nodes was performed for all patients. However, patients did not undergo para-aortic lymph node dissection routinely. Intraoperative pathological assessment of the proximal or distal ductal margins was performed using frozen-tissue sections. If malignant cells were found in the ductal margin, further resection of the bile duct was performed to the maximum extent possible.
Pathological Investigations
All surgical specimens were examined pathologically by senior pathologists. Each tumor was classified as well-differentiated, moderately differentiated, or poorly differentiated adenocarcinoma according to the predominant pathological grading of differentiation. Evaluation of pancreatic invasion, duodenal invasion, hepatic invasion, vascular invasion, or lymph node status was performed for all surgical specimens. The surgical margin was graded R1 if residual microscopic tumor was identified in the proximal or distal bile duct transaction line, the hepatic transaction line, or the dissected periductal soft tissue margins. The final stage of cholangiocarcinoma was graded on the basis of the seventh edition of the UICC tumor-nodemetastasis classification. 30
Adjuvant Gemcitabine-Based Chemotherapy
Postoperative AGC was administered to patients with UICC stage II, III, or IV disease beginning in 2002. This adjuvant chemotherapy regimen has been reported previously. 4, 7, 19 Patients who received postoperative adjuvant chemotherapy had 2 options after surgical resection: intravenous chemotherapy alone or intravenous and oral chemotherapy. Intravenous chemotherapy consisted of gemcitabine 700 mg/m 2 administered biweekly for 30 minutes by intravenous drip infusion. Patients who received intravenous and oral chemotherapy were given intravenous gemcitabine 700 mg/m 2 on day 1 and oral S-1 50 mg/m 2 for 7 consecutive days; this cycle was repeated every 14 days. If recurrent disease was identified in patients who completed AGC, they were given additional gemcitabine treatment. However, no patients received radiation therapy during the study period.
Immunohistochemistry for hENT1
Hematoxylin and eosin-stained slides containing specimens from each cholangiocarcinoma were reviewed, and a representative tumor region and the corresponding formalin-fixed paraffin-embedded tissue block were selected for use in a tissue microarray. Immunohistochemistry was performed using the streptavidin-peroxidase technique and Dako Envision+ system (Dako Cytomation GmbH, Hamburg, Germany), as described previously. 25, 26 To evaluate hENT1 expression, an affinity-purified polyclonal rabbit antibody against human hENT1 was purchased from the Abnova Co, Taipei, Taiwan. The immunohistochemical staining procedure was as follows: 4-μm tissue sections were cut from tissue microarray paraffin blocks, deparaffinized in xylene, and rehydrated through a series of ethanol solutions. After antigen retrieval by autoclaving (100 • C for 10 minutes in Dako Target Retrieval Solution High pH x1 for hENT1), sections were immersed in methanol containing 3% hydrogen peroxide for 15 minutes and incubated in protein blocking solution (Dako, Carpinteria, CA) for 10 minutes. Sections were incubated with appropriate dilutions of hENT1 antibody as a primary antibody (1:200 dilution for anti-hENT1 antibody) overnight at 4 • C. After being washed 3 times in phosphate-buffered saline (PBS), samples were incubated in labeled streptavidin-biotin polymer (Envision Plus, Dako) at room temperature for 60 minutes as a secondary antibody. After being washed 3 times in PBS, the slides were immersed for 10 minutes in 0.01% 3,3-diaminobenzidine solution in 50 mM Tris-HCl buffer with 10 mM hydrogen peroxide as a substrate. Sections were counterstained with Mayer's hematoxylin solutions, dehydrated through graded ethanol and xylene, and finally mounted. Negative controls consisted of sections incubated without the primary antibodies.
Immunohistochemical evaluation of hENT1 expression was confirmed independently by 2 observers (K.H. and M.Y.) in a blinded manner. Because hENT1 was strongly expressed in cell membranes of lymphocytes, 25, 26 these were used as an internal positive control. The intensity of hENT1 staining was scored as follows: grade 0, not stained; grade 1, weakly stained compared with the internal positive control; grade 2, stained as strongly as the internal positive control; and grade 3, strongly stained compared with the internal positive control. For evaluation of intratumoral hENT1 expression, if grade 2 or 3 staining was observed in more than 50% of tumor cells, the sample was considered to have high hENT1 expression, and if grade 0 or 1 staining was observed in more than 50% of tumor cells, the sample was considered to have low hENT1 expression ( Fig. 1 ). This cutoff value was determined on the basis of a previous report. 31 In cases of disagreement, consensus was reached by joint review.
Survival
Patients were followed regularly by undergoing a blood test, ultrasonography, or computed tomography. Diagnosis of recurrence was made on the basis of imaging findings. For patients who died, the survival time after surgery and cause of death were recorded. For surviving patients, postsurgical time and recurrence status were recorded. Overall survival was defined as the time from the date of surgical resection to the date of death or last follow-up. Disease-free survival was defined as the time from the date of surgical resection to the date of recurrence or last follow-up. The median follow-up time after surgery was 76 months (range, 9 -266 months) for all 105 patients.
FIGURE 1.
Immunohistochemical analysis of cholangiocarcinoma specimens for hENT1 expression. Cholangiocarcinoma with high human equilibrative nucleoside transporter 1 (hENT1) expression (A) and cholangiocarcinoma with low hENT1 expression (B). Adjacent lymphocytes (arrows) demonstrate strong staining, thereby providing a positive internal control (original magnification, X200; bar = 50 μm).
on univariate analysis were subjected to multivariate analysis using a Cox proportional hazards model. P < 0.05 was considered statistically significant. Statistical analyses were performed with Stat View 5.0 (SAS Institute, Cary, NC).
RESULTS
Patient Demographics and Tumor Characteristics
The 105 patients included 73 men (70%) and 32 women (30%), with a median age of 68 years (range, 37-85 years). This patient population contained 16 patients with intrahepatic cholangiocarcinoma, 49 with perihilar cholangiocarcinoma, and 40 with distal cholangiocarcinoma. Depending on the tumor location and tumor extent, a wide variety of surgical procedures were performed. Patients with intrahepatic cholangiocarcinoma underwent left hemihepatectomy (n = 8) and right hemihepatectomy (n = 8). Patients with perihilar cholangiocarcinoma underwent left hemihepatectomy (n = 18), right hemihepatectomy (n = 19), left trisectionectomy (n = 3), right trisectionectomy (n = 3), hilar bile duct resection (n = 5), and central bisegmentec-tomy (n = 1); caudate lobectomy was also performed for all patients with perihilar cholangiocarcinoma. Patients with distal cholangiocarcinoma underwent pylorus-preserving pancreatoduodenectomy (n = 32), conventional pancreatoduodenectomy (n = 5), and segmental bile duct resection (n = 3).
Tumors were identified as well-differentiated tubular adenocarcinoma in 49 patients (47%), moderately differentiated tubular adenocarcinoma in 36 patients (34%), and poorly differentiated tubular adenocarcinoma in 20 patients (19%). Pancreatic invasion, hepatic invasion, and vascular invasion were found in 28 patients (27%), 51 patients (49%), and 22 patients (21%), respectively. There were 56 tumors (53%) with lymph node metastasis and 49 tumors (47%) without lymph node metastasis. Eleven patients (10%) had involvement of the para-aortic lymph nodes. R0 and R1 resections were performed in 76 (72%) and 29 patients (38%), respectively. According to the tumor-node-metastasis system, 3 (3%), 5 (5%), 19 (18%), 28 (26%), 48 (46%), and 2 (2%) patients had pT1, pT2, pT2a, pT2b, pT3, and pT4 tumors, respectively; 27 (26%), 13 (12%), 21 (20%), 1 (1%), 5 (5%), 16 (15%), 6 (6%), 11 (10%), and 5 (5%) patients were diagnosed with stage II, IIA, IIB, III, IIIA, IIIB, IV, IVA, and IVB disease, respectively. A comparison of the clinicopathological factors among patients with intrahepatic, perihilar, and distal cholangiocarcinoma is presented in Table 1 . There were no significant differences in survival among patients in these 3 categories.
Delivery of AGC
Of the 105 patients, AGC was administered to 51 patients (49%). Forty-one patients received 10 or more cycles of adjuvant gemcitabine plus S-1 chemotherapy, and 7 patients received 10 or more cycles of gemcitabine alone. The other 3 patients had to stop AGC before 10 cycles of chemotherapy because of recurrent disease. However, they received at least 7 cycles of AGC. The median total dose of gemcitabine administered for the 51 patients was 18,000 mg , poorly  12  23  21  Lymph node metastasis  Yes  11  19  26  No  5  30  14  UICC pT factor  T 1, 2, 2a, 2b  13  35  7  T 3, 4  3  14  33  UICC stage  II, IIA, IIB  4  23  34  III, IIIA, IIIB, IV, IVA, IVB  12 
Relationships Between Clinicopathological Factors and Intratumoral hENT1 Expression
Of the 105 patients, high and low intratumoral hENT1 expression was found in 74 (70%) and 31 (30%) patients, respectively. For all 105 and 51 patients who received AGC, there were no significant differences in age, gender, tumor location, use of gemcitabine, residual tumor, pathological differentiation, lymph node status, UICC pT factor, and UICC stage between patients with high hENT1 expression and those with low hENT1 expression ( Table 2 ).
Relationship Between Overall Survival and Intratumoral hENT1 Expression
For all 105 patients, overall survival rates were 77% at 1 year, 41% at 3 years, and 33% at 5 years. Clinicopathological factors were investigated to determine their prognostic significance in all patients (Table 3 ). Univariate analysis of data from all 105 patients revealed that use of gemcitabine (P = 0.002), pathological differentiation (P = 0.001), lymph node metastasis (P = 0.001), and residual tumor (P < 0.001) was significantly associated with overall survival, whereas hENT1 expression was not (P = 0.143). One-, 3-, and 5-year survival rates of patients with high hENT1 expression and low hENT1 expression were 79%, 49%, 42% and 71%, 22%, 13%, respectively (Fig. 2) . The 4 significant factors were entered into a Cox proportional hazards model. The use of gemcitabine (hazard ratio [HR], 2.38, 95% confidence interval [CI], 1.42-3.98, P < 0.001), patholog-ical differentiation (HR, 2.04, 95% CI, 1.19-3.48, P = 0.009), and residual tumor (HR, 2.52, 95% CI, 1.40-4.55, P = 0.002) remained independent prognostic factors by multivariate analysis.
In addition, the prognostic significance of intratumoral hENT1 expression was also evaluated in the subgroups of patients who did and did not receive AGC, using univariate and multivariate survival analysis. For the 51 patients who received AGC, univariate survival analysis revealed that pathological differentiation (P = 0.025) and intratumoral hENT1 expression (P = 0.008) were significantly associated with overall survival, and intratumoral hENT1 expression was the only independent predictive factor by multivariate analysis (HR, 2.77; 95% CI, 1.12-6.81, P = 0.027, Table 4 ). For these, 1-, 3-, and 5-year survival rates of those with high hENT1 expression and low hENT1 expression were 94%, 68%, 59% and 87%, 12%, 0%, respectively (Fig. 3A) . In addition, disease-free survival of patients with high hENT1 expression was also significantly better than that of patients with low hENT1 expression (P = 0.024, 1-, 3-, and 5-year survival rates of patients with high hENT1 expression and low hENT1 expression were 77%, 55%, 50% and 73%, 16%, 0%, respectively). In contrast, no significant survival difference was observed between patients with high hENT1 expression and low hENT1 expression in the subgroup of patients who did not receive AGC (P = 0.894). In this group, 1-, 3-, and 5-year survival rates of patients with high hENT1 expression and those with low hENT1 expression were 66%, 32%, 29% and 56%, 25%, 13%, respectively (Fig. 3B ). Multivariate analysis showed that residual tumor was only an independent prognostic factor in patients who did not receive adjuvant chemotherapy (HR, 2.85; 95% CI, 1.32-6.13, P = 0.008, Table 5 ). In addition, among patients with high hENT1 expression (n = 74), overall survival of patients who received AGC was significantly better than that of those who did not (P = 0.002, Fig. 4A ), whereas among patients with low hENT1 expression (n = 31), no significant difference in overall sur-
Overall-survival curves of all patients (n = 105) with advanced cholangiocarcinoma, stratified by intratumoral human equilibrative nucleoside transporter 1 (hENT1) expression (P = 0.143).
vival was noted between patients who received AGC and those who did not (P = 0.525, Fig. 4B ).
DISCUSSION
Biliary carcinoma including cholangiocarcinoma is a relatively uncommon malignancy, and the resectability rate of this disease is not always high. 1 Therefore, reports concerning the prognostic impact of intratumoral hENT1 expression in patients with resected biliary carcinoma are scarce. 28, 29 In addition, these reports include different types of biliary carcinomas such as cholangiocarcinoma, gallbladder carcinoma, and ampullary carcinoma. In the current study, we elected to evaluate intratumoral hENT1 expression immunohistochemically only in patients with resected advanced cholangiocarcinoma, the number of which exceeded 100. To our knowledge, this is the first relatively large-scale study evaluating the prognostic value of intratumoral hENT1 expression in patients with resected cholangiocarcinoma.
At present, no randomized controlled study has confirmed the efficacy of adjuvant gemcitabine chemotherapy for patients with resected cholangiocarcinoma worldwide. However, an excellent survival benefit of gemcitabine on patients with unresectable biliary carcinoma was reported in several phase II and III studies. 16, 17, 32, 33 Therefore, gemcitabine is a promising anticancer drug for adjuvant chemotherapy after surgical resection of cholangiocarcinoma. Recently, we reported the results of retrospective analyses that demonstrated the usefulness of AGC for patients with biliary carcinoma or cholangiocarcinoma. 4, 7, 19 In the current cohort of 105 patients, the survival of those who received AGC was significantly better than that of those who did not, and the use of gemcitabine was an independent prognostic factor for patients with advanced cholangiocarcinoma. We believe that gemcitabine provides an excellent survival benefit for patients with resected cholangiocarcinoma. Several investigators have examined intratumoral hENT1 expression in various malignant tumors. According to these reports, the proportion of patients with high intratumoral hENT1 expression was 72% for breast cancer, 34 71% for lung cancer, 23 50% for bladder cancer, 22 45% for gastric cancer, 31 and 37% to 43% for pancreatic cancer. [24] [25] [26] [27] With regard to biliary carcinoma, an Italian group reported that high intratumoral hENT1 expression was found in 63% of patients with ampullary cancer 35 and 68% of patients with biliary tract cancer, 28 although these reports were based on a small number of patients. In the current study, 70% of patients with cholangiocarcinoma had high intratumoral hENT1 expression. The rate of high intratumoral hENT1 expression in biliary tract cancer might be higher than that in other gastrointestinal malignancies.
In this study, intratumoral hENT1 expression was not associated with patient demographic characteristics and tumor characteristics, including tumor location, tumor differentiation, UICC pT factor, and lymph node status. Farrell et al 26 reported that in an analysis of 198 patients with pancreatic cancer, there were no positive statistical associations between intratumoral hENT1 expression and baseline characteristics, including tumor stage. Similar results in patients with biliary cancer were reported by other investigators. 28, 29 Intratumoral hENT1 expression seems to be an independent variable different from other clinicopathological factors.
Santini et al 31 reported that in a retrospective analysis of 111 patients with resected gastric cancer who did not receive chemotherapy including gemcitabine, patients with high hENT1 expression had a shorter overall or disease-free survival than those with low hENT1 expression. In addition, they also reported a similar result in an immunohistochemical analysis of 41 tumors from patients with ampullary cancer. 29 On the basis of these results, they concluded that hENT1 expression itself was a useful molecular prognostic biomarker for these patients. In contrast, no significant associations between intratumoral hENT1 expression and overall survival were observed among the total population of patients and among those who did not receive AGC in the current study. The prognostic value of intratumoral hENT1 expression in patients who did not receive gemcitabine chemotherapy is controversial. Further studies on a larger number of patients with various cancers are needed to clarify this question.
Several reports have demonstrated a close correlation between intratumoral hENT1 activity and responsiveness to gemcitabine in some types of malignant tumors. Oguri et al 23 reported that responses to gemcitabine-based chemotherapy were evident in patients with high hENT1 expression but not in patients with no hENT1 expression in an analysis of 24 patients with non-small cell lung cancer. Matsumura et al 22 analyzed 40 patients with bladder cancer treated with gemcitabine-/cisplatin-based combination chemotherapy and reported that the overall survival of patients with high hENT1 expression was significantly higher than that of patients with low hENT1 expression, and hENT1 expression was an independent predictive factor by multivariate analysis. Similar results were reported in patients with unresectable or resected pancreatic cancer. [24] [25] [26] [27] Marechal et al 27 stated that in an analysis of 45 pancreatic cancer patients treated with postoperative adjuvant gemcitabine-based chemoradiation therapy, patients with high hENT1 expression had significantly longer disease-free and overall survival than those with low hENT1 expression, and hENT1 expression was the only independent FIGURE 3. Overall survival curves of patients with advanced cholangiocarcinoma who received AGC (A, n = 51) and of those who did not (B, n = 54), stratified by intratumoral hENT1 expression (A, P = 0.008; B, P = 0.894).
predictor for disease-free and overall survival. In addition, Farrell et al 26 reported that the overall survival of patients with high hENT1 expression was significantly better than that of patients with low hENT1 expression among 91 patients who received adjuvant chemoradiation with gemcitabine but not among 107 patients who received adjuvant chemoradiation with 5-fluorouracil (5-FU).
However, in biliary cancer, only one study has shown the association between hENT1 expression and chemosensitivity to gemcitabine using immunohistochemistry. That study, of 31 patients with unresectable biliary tract cancer who received gemcitabine-based chemotherapy, demonstrated that time to progression was significantly better in patients with high hENT1 expression than in patients with low hENT1 expression, but the difference in overall survival did not reach statistical significance. 28 In the current study, we analyzed 105 patients with cholangiocarcinoma including 51 patients who received AGC and 54 patients who did not. As a result, among patients who received AGC, patients with high intratumoral hENT1 expression had significantly better survival than those with low intratumoral hENT1 expression, and intratumoral high hENT1 expression was independently associated with longer overall survival among patients who received AGC. In addition, the current study showed that gemcitabine chemotherapy brought a significant survival benefit to patients with high intratumoral hENT1 expression but not to patients with low intratumoral hENT1 expression. On the basis of these results, we believe that intratumoral hENT1 expression is a potent predictive biomarker of survival in AGC for patients with resected cholangiocarcinoma. Further modifications of postoperative adjuvant chemotherapy regimens for patients with low intratumoral hENT1 expression may be required to improve the long-term survival of these patients.
In this study, S-1 was also administered to most patients who received gemcitabine. S-1 is an oral anticancer drug consisting of tegafur as the prodrug of 5-FU. 36 We therefore assume that overall survival may have been influenced by S-1 in addition to gemcitabine. However, there have been no reports that prove a relationship between intratumoral hENT1 expression and responsiveness to 5-FU. As mentioned earlier, hENT1 protein expression was reported to have no association with increased disease-free survival and overall survival in pancreatic cancer patients who received 5-FU. 26 We believe that the combined use of S-1 and gemcitabine did not affect the results of this study. The limitation of the current study is that it is not based on prospective evaluation in randomized clinical trials. This study is a retrospective study with a retrospectively collected data and tissue. In addition, other biomarkers such as deoxycytidine kinase, 5'nucleotidase, cytidine deaminase, and ribonucleotide reductase subunits M1 and M2 have been reported to be associated with response to gemcitabine in pancreatic cancer. 24 However, there are no clinical reports that demonstrate the predictive impact of these biomarkers in biliary carcinoma including cholangiocarcinoma. Further prospective studies on a larger number of patients are needed to determine the predictive value of these markers and their relationship with hENT1 expression.
In conclusion, high intratumoral hENT1 expression was closely associated with better overall survival in patients with advanced cholangiocarcinoma who were treated with AGC after surgical resection. Intratumoral hENT1 expression is a relevant predictive biomarker for patients with resected advanced cholangiocarcinoma who receive AGC. Analysis of intratumoral hENT1 expression may enable the implementation of an optimal adjuvant chemotherapy regimen to patients with cholangiocarcinoma in the future.
